


AMENDMENTS TO THE CLAIMS

Please cancel the existing claims and substitute the following claims:

1. A compound of the general formula




I

or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

R1 is H, C₁₋₆alkyl, C₁₋₆alkylNR₅R₆, C₁₋₆alkylNR₅COR₆, C₁₋₆alkylNR₅SO₂R₆, C₁₋₆alkylCO₂R₅, C₁₋₆alkylCONR₅R₆, where R₅ and R₆ are each independently H, C₁₋₄alkyl, aryl, hetaryl, C₁₋₄alkylaryl, C₁₋₄alkylhetaryl or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR₇ and R₇ is selected from H, C₁₋₄alkyl;

R₂, R₃ and R₄ are each independently H, halogen, C₁₋₄alkyl, OH, OC₁₋₄alkyl, CF₃, OCF₃, CN, C₁₋₄alkylNR₈R₉, OC₁₋₄alkylNR₈R₉, OCONR₈R₉, NR₈R₉, NR₈COR₉, NR₁₀CONR₈R₉, NR₈SO₂R₉, COOR₈, CONR₈R₉; and R₈, R₉ are each independently H, C₁₋₄alkyl, C₁₋₄alkyl cycloalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR₁₁; R₁₀ and R₁₁ are independently selected from H, C₁₋₄alkyl, CF₃;

alternatively, two of R₂, R₃ and R₄, when located on adjacent carbon atoms, may be joined to form a ring system selected from:



where R12 is selected from H, C₁₋₄ alkyl, CF₃ and R13 is selected from H, C₁₋₄ alkyl, CF₃, COR14, SO₂R14; and R14 is selected from H, C₁₋₄ alkyl;


Q is a bond, or C₁₋₄ alkyl;

W is selected from H, C₁₋₄alkyl, C₂₋₆alkenyl; where C₁₋₄alkyl or C₂₋₆alkenyl may be optionally substituted with C₁₋₄alkyl, OH, OC₁₋₄alkyl, NR15R16; and R15, and R16 are each independently H, C₁₋₄ alkyl, C₁₋₄ alkyl cycloalkyl, C₁₋₄ alkyl cyclohetalkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17 and R17 is selected from H, C₁₋₄ alkyl;

A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C₁₋₄ alkyl, CF₃, aryl, hetaryl, OCF₃, OC₁₋₄alkyl, OC₂₋₅alkylNR18R19, Oaryl, Ohetaryl, CO₂R18, CONR18R19, NR18R19, C₁₋₄ alkylNR18R19, NR20C₁₋₄alkylNR18R19, NR18COR19, NR20CONR18R19, NR18SO₂R19; and R18, R19 are each independently H, C₁₋₄ alkyl, C₁₋₄ alkyl cyclohetalkyl, aryl, hetaryl, C₁₋₄alkyl aryl, C₁₋₄ alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21; and R20 is selected from H, C₁₋₄ alkyl; and R21 is selected from H, C₁₋₄ alkyl; and

Y is selected from H, C₁₋₄alkyl, OH, NR22R23, and R22, and R23 are each independently H, C₁₋₄ alkyl.

2. A compound according to claim 1 of the general formula II:



II

or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

R1 is H, C₁₋₆alkyl, C₁₋₆alkylNR3R4, where R3 and R4 are each independently H, C₁₋₄alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR5 and R5 is selected from H, C₁₋₄alkyl;

A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C₁₋₄alkyl, CF₃, aryl, hetaryl, OCF₃, OC₁₋₄alkyl, OC₂₋₅alkylNR6R7, Oaryl, Ohetaryl, CO₂R6, CONR6R7, NR6R7, C₁₋₄alkylNR6R7, NR8C₁₋₄alkylNR6R7, NR6COR7, NR8CONR6R7, NR6SO₂R7; and R6, R7 are each independently H, C₁₋₄alkyl, C₁₋₄alkyl cyclohetalkyl, aryl, hetaryl, C₁₋₄alkyl aryl, C₁₋₄alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR9; and R8 is selected from H, C₁₋₄alkyl; and R9 is selected from H, C₁₋₄alkyl;



R2 is 0-2 substituents independently selected from halogen, C₁₋₄alkyl, OH, OC₁₋₄alkyl, CF₃, OCF₃, CN, C₁₋₄alkylNR10R11, OC₁₋₄alkylNR10R11, CO₂R10, CONR10R11, NR10R11, NR10COR11, NR12CONR10R11, NR10SO₂R11; and R10, R11 are each independently H, C₁₋₄alkyl; and R12 is selected from H, C₁₋₄alkyl;











Y is H, OH, NR12R13,; and R12, and R13 are each independently H, C₁₋₄alkyl, or may be joined to form an optionally substituted 3-6 membered ring optionally containing an atom selected from O, S, NR14 and R14 is selected from H, C₁₋₄alkyl;

n = 0-4;

W is selected from H, C₁₋₄alkyl, C₂₋₆alkenyl; where C₁₋₄alkyl or C₂₋₆alkenyl may be optionally substituted with C₁₋₄alkyl, OH, OC₁₋₄alkyl, NR₁₅R₁₆; and R₁₅, and R₁₆ are each independently H, C₁₋₄ alkyl, C₁₋₄ alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR₁₇ and R₁₇ is selected from H, C₁₋₄ alkyl.

3. A compound according to claim 1 where W is C₁₋₄ alkyl or C₁₋₄alkylamino and at least a portion of the compound possesses *S* chirality at the chiral carbon bearing W.
4. A compound according to claim 3 wherein the compound is a mixture of R and S isomers and the mixture comprises at least 70% of the S isomer.
5. A compound according to claim 4 wherein the compound comprises at least 80% of the S isomer.
6. A compound according to claim 4 wherein the compound comprises at least 90% of the S isomer.
7. A compound according to claim 4 wherein the compound comprises at least 95% of the S isomer.
8. A compound according to claim 4 wherein the compound comprises at least 99% of the S isomer.
9. A compound according to claim 1 wherein the compound is selected from the group consisting of:





10. A composition comprising a carrier and at least one compound of claim 1.
11. A method of treating a hyperproliferation-related disease state in a subject, the method comprising administering a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutical composition thereof.
12. A method according to claim 11 wherein the hyperproliferation-related disease state is treatable by the modulation of microtubule polymerisation.
13. A method according to claim 11 wherein the hyperproliferation-related disease state is selected from the group consisting of:

Atopy, such as Allergic Asthma, Atopic Dermatitis (Eczema), and Allergic Rhinitis; Cell Mediated Hypersensitivity, such as Allergic Contact Dermatitis and Hypersensitivity Pneumonitis; Rheumatic Diseases, such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis, Juvenile Arthritis, Sjögren's Syndrome, Scleroderma, Polymyositis, Ankylosing Spondylitis, Psoriatic Arthritis; Other autoimmune diseases such as Type I diabetes, autoimmune thyroid disorders, and Alzheimer's disease; Viral Diseases, such as Epstein Barr Virus (EBV), Hepatitis B, Hepatitis C, HIV, HTLV 1, Varicella-Zoster Virus (VZV), Human Papilloma Virus (HPV); Cancer, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma, and carcinomas forming

from tissue of the breast, prostate, kidney, bladder or colon, and neoplastic disorders arising in adipose tissue, such as adipose cell tumors, e.g., lipomas, fibrolipomas, lipoblastomas, lipomatosis, hibemomas, hemangiomas and/or liposarcomas; infectious diseases such as viral, malarial and bacterial infections; vascular restenosis; inflammatory diseases, such as autoimmune diseases, glomerular nephritis myocardial infarction and psoriasis.

14. A method of modulating microtubule polymerisation in a cell which method comprises administering a compound according to claim 1.
15. A method of modulating microtubule polymerisation in a cell which method comprises administering a compound according to claim 2.
16. A method of treating a hyperproliferation-related disease state in a subject, the method comprising administering a therapeutically effective amount of at least one compound of claim 2 or a pharmaceutical composition thereof.